Hims & Hers Health, Inc. Class A (HIMS) Covered Calls

Hims & Hers Health, Inc. is a leading multi-specialty digital health platform that connects consumers to licensed healthcare professionals. The company provides personalized access to treatments for a variety of conditions, including sexual health, hair loss, dermatology, mental health, and weight management. By integrating telehealth, pharmacy services, and data-driven insights, Hims & Hers aims to make high-quality, specialized care affordable and accessible to millions of individuals.

You can sell covered calls on Hims & Hers Health, Inc. Class A to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for HIMS (prices last updated Fri 3:35 PM ET):

Hims & Hers Health, Inc. Class A (HIMS) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
15.66 -0.16 15.66 15.67 20.5M 30 3.6
Covered Calls For Hims & Hers Health, Inc. Class A (HIMS)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Mar 20 16 1.72 13.95 12.3% 155%
Apr 17 16 2.31 13.36 17.3% 111%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Hims & Hers Health, Inc. operates a direct-to-consumer digital health platform designed to simplify the healthcare experience. The company’s model integrates telehealth consultations with a vertically integrated pharmacy fulfillment network, allowing customers to receive tailored treatment plans and medications at their doorstep. Core service areas include "Hims" for men and "Hers" for women, with a focus on sensitive health categories such as hair loss, sexual dysfunction, skincare, and mental health. A significant recent growth driver is the company’s expansion into personalized weight management, including the provision of compounded GLP-1 medications and access to a broad suite of metabolic health tools.

In February 2026, the company significantly expanded its international footprint by entering into an agreement to acquire Eucalyptus, a major Australian-based telehealth provider, for approximately $1.15 billion. This acquisition accelerates the firm’s strategy to become a global consumer health leader, adding over 775,000 customers and providing immediate scale in Australia, Japan, and the United Kingdom. The company’s proprietary "MedCloud" platform utilizes AI to assist providers in personalizing dosages and treatment durations, while its subscription-based revenue model ensures a high level of recurring income and customer lifetime value.

Competitive Landscape

The digital health and wellness sector is rapidly evolving, with competition from traditional telehealth providers, retail pharmacies, and specialized health platforms. Hims & Hers differentiates itself through high-end branding and a focus on personalized, discreet care. Primary competitors listed on the NYSE or NASDAQ with active, liquid options chains include Teladoc Health, CVS Health, and BrightSpring Health Services. In the high-growth weight-loss and longevity sector, the company also overlaps with Eli Lilly and Novo Nordisk, which manufacture the branded GLP-1 medications that compete with Hims & Hers’ personalized alternatives.

Strategic Outlook and Innovation

Strategic priorities for 2026 are centered on "Global Expansion and Preventative Care." Following the Eucalyptus acquisition, the company is focused on harmonizing its global infrastructure and scaling its diagnostic capabilities through "Hims & Hers Labs," which offers at-home testing for biomarkers related to metabolic health, longevity, and hormonal balance. Innovation efforts are heavily directed toward "Agentic AI" applications that streamline the patient intake process and provide real-time engagement between consumers and healthcare providers, reducing the friction typically associated with traditional medical visits.

The company is navigating a complex regulatory environment, particularly concerning the compounding of high-demand medications. Its strategy involves working closely with accredited 503B compounding facilities to ensure the highest standards of safety and efficacy while maintaining its ability to offer affordable, customized formulations. By moving toward a more holistic, "longevity-first" approach, Hims & Hers seeks to transform from a single-condition treatment platform into a comprehensive health partner for its subscribers. Long-term goals include achieving greater operating leverage through increased automated fulfillment and maintaining a robust cash position to fund further strategic M&A in the international digital health space.